FDA Approves Novel Glucose Monitoring System
The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.
Related News Articles
Headline
The AHA June 14 sent a letter to the Senate Finance Committee, responding to questions included in a white paper the committee wrote on chronic care through…
Headline
The Centers for Disease Control and Prevention June 13 issued a Health Alert Network Health Advisory following a federal health care fraud indictment against…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
The House Energy and Commerce Subcommittee on Health May 16 passed a number of bills during a markup session, including AHA-supported legislation. The…
Headline
AHA submitted a statement May 8 to the House Ways and Means Committee for a markup session on proposed legislation impacting telehealth access for patients and…
Headline
AHA urges Congress to extend Affordable Connectivity Program to support digital health care services
In a letter submitted May 7 to a bipartisan group of senators, AHA urged Congress to extend the Affordable Connectivity Program, which provides benefits toward…